Bris­tol My­ers Squibb scores TYK2 OK; ARCH backs mR­NA plat­form play; Il­lu­mi­na’s $8B co­nun­drum; Siz­ing up Al­ny­lam's win; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Try­ing to keep up with all the news com­ing out of ES­MO? Well, oth­er than the spe­cial event sec­tion be­low, we’ll al­so be up­dat­ing the web­site through­out the week­end. If you pre­fer a sum­ma­ry, join Ar­salan Arif and John Car­roll for a vir­tu­al re­cap and analy­sis on Mon­day, when we will al­so pub­lish a spe­cial re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER